Ilsung Is Co., Ltd. (KRX:003120)

South Korea · Delayed Price · Currency is KRW

20,200

+100 (0.50%)

Aug 3, 2026, 3:30 PM KST

-14.59% (1Y)

Market Cap	140.77B -14.6%
Revenue (ttm)	64.38B -7.6%
Net Income	1.20B -92.1%
EPS	173.16 -92.3%
Shares Out	6.97M
PE Ratio	116.65
Forward PE	n/a
Dividend	1,200.00 (5.91%)
Ex-Dividend Date	Dec 29, 2025

Volume	2,435
Open	20,100
Previous Close	20,100
Day's Range	19,950 - 20,550
52-Week Range	17,120 - 29,300
Beta	-0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Ilsung Is

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular sys... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1954

Country South Korea

Stock Exchange Korea Stock Exchange

Ticker Symbol 003120

Full Company Profile

Financial Performance

In 2025, Ilsung Is's revenue was 64.29 billion, a decrease of -6.85% compared to the previous year's 69.02 billion. Earnings were 1.17 billion, a decrease of -91.10%.

Financial Statements